Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
OBJECTIVE
Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects. Our aim was to determine and characterize preferences for these two drugs in patients with BE.


METHODS
Preferences data were collected from recruited BE patients using a customized questionnaire, which incorporated standard risk communication techniques. Summary profiles outlined the benefits and harms of celecoxib and aspirin presented anonymously. Both drugs were portrayed as reducing the risk of EAC and increasing the risk of GI events. However, celecoxib increased the risk of myocardial infarction (MI) while aspirin reduced the risk. Factors influencing patient acceptance of each drug were analyzed.


RESULTS
One hundred of 109 (92%) subjects completed the study. Under base case conditions, 15% stated that they would take celecoxib and 76% aspirin (P < 0.0001). Patients identified the greater risk of MI as the primary reason for their unwillingness to take celecoxib and the lower risk of EAC for aspirin. Even in scenarios in which the benefits of celecoxib were improved and the harms reduced, a majority continued to find it unacceptable.


CONCLUSIONS
A majority of those surveyed stated that they would take aspirin but would not take celecoxib. Most patients are interested in EAC chemoprevention, but the amount of protection and the side effect profile of a drug determine its acceptability. These data can inform physicians regarding the tradeoffs patients are willing to consider for chemoprevention.
Hur
Chin
C
Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Broughton
Darcy E
DE
Ozanne
Elissa
E
Yachimski
Patrick
P
Nishioka
Norman S
NS
Gazelle
G Scott
GS
D000230:Adenocarcinoma / Q000473:pathology / Q000517:prevention & control*; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D001471:Barrett Esophagus / Q000188:drug therapy* / Q000473:pathology; D002318:Cardiovascular Diseases / Q000517:prevention & control; D000068579:Celecoxib; D018890:Chemoprevention / Q000379:methods; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D018450:Disease Progression; D004359:Drug Therapy, Combination; D004938:Esophageal Neoplasms / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011230:Precancerous Conditions; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D012307:Risk Factors; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib; D001241:Aspirin
Heart. 2001 Mar;85(3):265-71
11179262
Postgrad Med. 1999 Mar;105(3):100-2, 105-8, 110
10086036
N Engl J Med. 2006 Aug 31;355(9):873-84
16943400
Ann Intern Med. 2002 Jan 15;136(2):161-72
11790072
Gastroenterology. 2003 Jan;124(1):47-56
12512029
Gastroenterology. 2002 Apr;122(4):1101-12
11910360
Ann Intern Med. 2005 Feb 1;142(3):157-64
15684203
J Natl Cancer Inst. 2007 Apr 4;99(7):545-57
17405999
N Engl J Med. 1989 Jul 20;321(3):129-35
2664509
Gastroenterology. 2000 Aug;119(2):333-8
10930368
Gastroenterology. 2005 Aug;129(2):429-36
16083700
BMJ. 2002 Apr 6;324(7341):827-30
11934777
J Gen Intern Med. 1993 Oct;8(10):543-8
8271086
JAMA. 1999 Nov 24;282(20):1921-8
10580457
Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102
9488582
BMJ. 2002 Sep 21;325(7365):619
12242171
BMJ. 2006 Jun 3;332(7553):1302-8
16740558
Ann Intern Med. 2006 Mar 7;144(5):326-36
16520473
J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
9747868
Med Decis Making. 2002 Nov-Dec;22(6):464-74
12458976
Cancer. 2004 Jul 1;101(1):189-97
15222006
Dis Esophagus. 2007;20(3):265-8
17509125
J Natl Cancer Inst. 2002 Mar 20;94(6):422-9
11904314
Stroke. 2006 Feb;37(2):345-50
16397184
J Natl Cancer Inst. 2004 Feb 18;96(4):316-25
14970280
Lancet. 1999 Jan 9;353(9147):89-92
10023892
Gastroenterology. 2003 Jun;124(7):1758-66
12806608
N Engl J Med. 2002 Jun 27;346(26):2033-8
12087138
N Engl J Med. 2006 Aug 31;355(9):885-95
16943401